Navigation Links
'Watchful Waiting' Safe With Low-Risk Prostate Cancers
Date:3/16/2009

Study suggests close monitoring offers some men better quality of life

MONDAY, March 16 (HealthDay News) -- Refusing immediate treatment can be safe for men with low-risk prostate cancer if they're closely monitored, new research finds.

The multi-center study of American and Canadian patients was conducted between 1991 and 2007.

"When or if to treat men with low-risk prostate cancer has always been a challenging question that faces patients and urologists," study author Dr. Scott Eggener, an assistant professor of surgery at the University of Chicago Medial Center, said in a news release from the university. "Some men may be rushing into treatment that won't necessarily benefit them, prevent problems or prolong life. Close observation in certain patients may provide and maintain quality of life without increasing the chances of the cancer spreading."

Between 20 percent and 50 percent of American men diagnosed with prostate cancer will eventually die from a cause other than their prostate cancer, he noted. This shows that a large number of patients don't benefit from treatment for their prostate cancer.

The 262 men in this study who decided on "watchful waiting" instead of immediate treatment met the following criteria: under age 75; prostate specific antigen (PSA) below 10 ng/ml; clinical stage T1-T2a; Gleason score 6 or below; and three or fewer positive cores at diagnostic biopsy. The patients underwent a restaging biopsy and had no treatment for six months following the repeat biopsy. They then had physical exams and PSA tests every six months with biopsies recommended every one to two years.

Of the men in the study, 43 eventually decided to have treatment or had evidence of cancer progression that prompted a doctor's recommendation to begin treatment. Following radiation or surgery, all but one of those 43 patients were cured of their prostate cancer. The remaining 219 patients remained on watchful waiting without evidence of cancer progression.

"Active surveillance with delayed treatment, if necessary, for select patients appears to be safe and associated with a low risk of metastatic spread," the researchers concluded.

The study was published in the March 16 issue of Urology.

"Active surveillance is not a total disregard for patients with prostate cancer. Instead, it identifies men unlikely to be affected by their cancer and encourages frequent monitoring, and then starting therapy at a later appropriate time if needed. Cure rates appear to be identical when these men choose immediate treatment or delayed treatment when prompted by new information about their condition," Eggener said.

More information

The Prostate Cancer Foundation has more about watchful waiting.



-- Robert Preidt



SOURCE: University of Chicago Medical Center, news release, March 16, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Radiation seed implant decreases risk of death over watchful waiting
2. Keep a Watchful Eye on Sugary Beverage Consumption
3. Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab
4. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
5. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
6. New Heart Pump Helps Women Awaiting Transplants
7. Governor Rendell Offers Coverage to 29,000 on AdultBasic Waiting List; Unveils New Policy to Improve Quality of Care for the Low-Income and Pennsylvanians With Disabilities
8. Blacks awaiting lung transplants more likely to die or be denied than whites
9. Blacks Awaiting Lung Transplants Face Poorer Outcomes
10. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
11. Hidden heart condition increases the risk of death in patients waiting for kidney transplants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Watchful Waiting' Safe With Low-Risk Prostate Cancers
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... ... 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection ... Campagna Academy in a charity drive to provide for at-risk children and teens in ... Academy is a nonprofit organization that has offered critical programs to at-risk and foster ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body of ... its product now available through Jet.com. , After 25 years of development, the ... is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
Breaking Medicine Technology: